University of Cambridge, Cambridge, United Kingdom
Simon Pacey , Mark David Linch , Howard Kynaston , Anne Warren , Alex Freeman , Ruth Tysoe , Greg Shaw , Krishna Narahari , Satish Kumar , Henno Martin , Bihani Kularatne , Vincent Gnanapragasam , Barry Davies , Josephine Khan , Ola Bratt , Harveer Dev , Charles Massie , Nimish Shah
Background: Novel agents given prior to RP allows the study of drug effect(s) in primary human prostate cancer (PC), supporting future clinical study development. Pre-clinical and clinical data (mostly in setting of castration resistant PC) support PARP ± androgen inhibition as therapy for some patients (pt). We undertook a study of olaparib (O) ± degarelix (D) prior to RP. Methods: 20 evaluable (pre and post RP tissue available with 86% dose compliance) pt randomised 1:1 to O or O+D. Primary endpoint: measure PARP inhibition by IHC. Secondary endpoints were feasibility, safety, tolerability. Exploratory objectives: changes PSA, circulating tumour DNA & intra-tumoral immune cells. Men, due for RP, with high volume or aggressive PC, consented and were treated with O (300mg bd) 15 days ± D (240mg once), prior to RP. Diagnostic biopsy and RP tissue were collected. Adverse events (AE) were graded according to CTCAE v4 and followed up to resolution or 6-weeks post RP. Results: 24 men recruited, 4 not evaluable (opted radiotherapy, surgery date altered, not by AE). Interim results are presented of available data. Conclusions: 2 weeks of O (± D) can be given prior to RP with acceptable safety profile. Exploratory analyses of tumour tissue are ongoing however, preliminary data confirm PSA drop noted for pt on both regimens. While expected for O+D this is the first report of PSA changes following a short course of single agent PARPi (O) in pt with local/ hormone sensitive PC. Clinical trial information: NCT02324998
O | O+D | |
---|---|---|
Age (mean/ range) yr | 60.7 (48-72) | 62.6 (47-72) |
D’Amico criteria | ||
- Intermediate risk | 55% | 73% |
- High risk | 45% | 27% |
Performance Status | ||
- ECOG 0 | 100% | 91% |
- ECOG 1 | 0% | 9% |
Majority of related AEs Grade (Gr) 1, none > Gr 2. Commonest AE were O: fatigue, nausea & vomiting, O+D: injection site reaction, fatigue & nausea. No RP were delayed by AE. PSA declined from baseline in 8/8 pt O+D and 3/9 (11, 17 & 47%) pt O. Biomarker analysis are ongoing.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Ted Van Alstyne
2023 ASCO Quality Care Symposium
First Author: Nicholas Moffett
2021 Genitourinary Cancers Symposium
First Author: Tian Zhang
2024 ASCO Genitourinary Cancers Symposium
First Author: Rana R. McKay